Traitement de la maladie veineuse thromboembolique au cours du cancer Mise à jour Avril 2023: Treatment of cancer associated thrombosis. 2023 update of the french guidelines

In recent years, knowledge about cancer associated thrombosis has evolved considerably.Practical guidelines were drafted on the initiative of the INNOVTE FCRIN Network, led by the French Speaking Society of Respiratory Diseases (SPLF), by a coordinating group, a writing group, and a review group, with the involvement of different scientific societies practicing in various settings. The method followed the "Clinical Practice Guidelines" process of the French National Authority for Health (HAS).After a literature review, guidelines were formulated, improved, and then validated by the working groups. These guidelines addressed multiple aspects of the disease and management from the data of available clinical trials and observational studies : epidemiology, initial treatment, treatment duration, extended treatment, recurrent thrombosis, central venous catheter thrombosis, incidental thrombosis, treatment in case of thrombocytopenia.These evidence-based guidelines are intended to guide the practical management of patients with cancer associated thrombosis.